A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

California Gov. Gavin Newsom on Friday signed a package of legislation meant to strengthen mental health and substance abuse ...

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...

Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

Children who are overweight or obese are more likely to develop schizophrenia as adults, according to a recent study. But adults with excess weight seem to have a lower risk of both schizophrenia ...

London: Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function in patients with schizophrenia, after it did not ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. The biotech was unable to replicate the cognition signal it saw in an earlier midphase study, prompting it to stop development of ...

The trial enrolled adults with cognitive impairment associated with schizophrenia. Credit: PeopleImages.com – Yuri A / Shutterstock. Neurocrine Biosciences has reported that its Phase II ERUDITE ...

In the previous study, luvadaxistat failed to meet, opens new tab the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving ...